Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12429186 | 0.88 | LMNA (0.35) | LMNARAB9AKMT2ANPC1HPGD | |
| SCHEMBL16518358 | 0.85 | MAPK1 (0.43) | LMNARAB9AKMT2ANPC1HPGD | |
| SCHEMBL11455772 | 0.85 | CSNK2A1 (0.43) | LMNARAB9ANPC1HPGDCSNK2A1 | |
| SCHEMBL27404540 | 0.84 | MAPK1 (0.38) | LMNAKMT2AHPGDSMN1; SMN2NPY1R | |
| SCHEMBL7712897 | 0.83 | PTGDR2 (0.42) | LMNAHPGDSMN1; SMN2NPSR1NPY1R | |
| SCHEMBL8317291 | 0.82 | CSNK2A1 (0.44) | HPGDSMN1; SMN2CSNK2A1ALDH1A1MAPT | |
| SCHEMBL27393106 | 0.82 | DHFR (0.37) | NPY1RNPY2RPDE4B | |
| SCHEMBL10058953 | 0.82 | ALDH1A1 (0.41) | LMNAKMT2ANPY1RNPY2RALDH1A1 | |
| SCHEMBL7167776 | 0.82 | CSNK2A1 (0.41) | RAB9ANPC1HPGDCSNK2A1ALDH1A1 | |
| SCHEMBL7802721 | 0.82 | PTPN1 (0.37) | HPGDSMN1; SMN2NPY1RNPY2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-116744918-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4221702-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072512-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015065937-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CBR1 | LMNA 2076/4885RAB9A 226/4885KMT2A 3050/4885 |
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | LMNA 1218/4885RAB9A 4552/4885KMT2A 3736/4885 |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | LMNA 1286/4885RAB9A 1724/4885KMT2A 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.